<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Sydney_Australia_Patent_Law skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Sydney Australia/Patent Law</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="navbar navbar-inverse navbar-fixed-top" style="margin-top:15px;"><DIV class="container"><DIV class="navbar-collapse collapse"><UL class="nav navbar-nav navbar-right"><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Team">Team </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Team">About Us</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Attributions">Attributions</A></LI></UL><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Design">Design </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Design">Project Design</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Applied_Design">Applied Design</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated">Integrated Human Practices</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Entrepreneurship">Entrepreneurship</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Patent_Law">Patent Law</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Description">Project </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Description">Description</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Experiments">Protocols</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Safety">Safety</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Notebook">Notebook</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Results">Results</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Demonstrate">Demonstrate</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Model">Model </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Model">Our Modelling</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Human_Practices">Communications </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/HP/Silver">Human Practices</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Engagement">Engagement</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Collaborations">Collaborations</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Interlab">Interlab</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Rate_My_Gel">Rate My Gel</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Parts">Parts </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Parts">Our Parts</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Composite_Part">Our Composite Parts</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Basic_Part">Our Basic Parts</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Improve">Part Improvement</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Medals">Medals </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Medals"> Medals</A></LI></DIV></DIV></DIV><DIV class="container-fluid"><DIV class="row"><DIV class="content" id="please"><CENTER><H1>Aim</H1></CENTER><CENTER><H4>In constructing the sequence of a single chain insulin we had to ensure that our sequence was not under any existing patents so that we could submit our sequence into the Open Source iGEM registry. With a bit of help from <A href="http://www.maxpat.com/about-us-2/our-team/leonard-mancini/">Maxwell Lawyers</A> we went through several <U>single chain</U> insulin patents, <U>method</U> patents and existing patents for current insulin dispensing <U>devices/therapeutics</U> using the FDA orange book. The goal was to make sure our work did <I>not</I> come under any existing patents so we would not infringe any ownership rights. Importantly, we recognise the difficulty of being thorough with all existing patents and the content provided is not intended to be legal advice and should not be used as such. To determine whether you are infringing a patent; the best course of action is to seek a qualified patent lawyer. To examine the way we approached patents - please <I>click on the links below</I> for easy navigation to each section.</H4></CENTER></DIV></DIV><DIV class="row"><DIV class="content" id="please"><CENTER><H1>How to read a patent </H1></CENTER><CENTER><H4>After our chat with Uppsala (check it out in <A href="https://2017.igem.org/Team:Sydney_Australia/Collaborations">collaborations</A>), our team realised that patents are a very poorly understood area, particularly for young aspiring scientists with new and challenging ideas. With a resident legal student in our team - we created a quick checklist on <I>How to read a patent</I></H4></CENTER><H2><CENTER>KEY CONSIDERATIONS</CENTER></H2><H4><CENTER><B>1.</B>  Patents give an exclusive commercial right to the invention aka. a monopoly 
<B>2.</B>  The &quot;claims&quot; of a patent, detail what is covered by the patent. 
<B>3.</B>  If it is NOT in the patent; it is NOT patentable.</CENTER></H4></DIV></DIV><DIV class="row"><DIV class="content" id="please"><DIV class="col-xs-10"><H3>And it is with this checklist that we approached the analysis of a wide range of patents below.</H3></DIV></DIV></DIV><DIV class="row"><DIV class="content" id="please"><CENTER><H1><B>1.</B> Single Chain Insulin Patents</H1></CENTER><CENTER><H4>Although our team attempted to be thorough, we recognise that not all patents can be checked. However, we targeted patents with the greatest relevance to avoid legal suits that may arise. Our primary concern was <U>single chain</U> insulin patents since they have only been recently explored in greater depth and quoted to have benefits like enhanced thermostability. As these single chain insulins are likely to be the next insulin product in the market, we wanted to create one, outside the scope of existing patents, to characterise and compare our product.
 Importantly there is an exception in patents for research purposes. This means that if the work you performed is for research purposes only, you do not infringe the relevant patent. You can<U>not</U> however, submit the part into the open source registry or try and commercialise it. As we are submitting 'Winsulin,' our single chain insulin, it must not be patented.</H4><H1>HELP RUBY HELP RUBY HELP RUBY</H1>.</CENTER></DIV><DIV class="patent_1 box"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:
normal"><SPAN lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">DIMARCHI ET AL.</SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Single Chain Insulin with high
bioactivity</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Patent No: <B style="mso-bidi-font-weight:
normal">US 9458,220 B2</B></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">October <SPAN class="GramE">4<SUP>th</SUP></SPAN>
2016</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext 0.5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:16.25pt"><TD width="50%" style="width:50.94%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#FFF2CC;mso-background-themecolor:accent4;
  mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">CLAIM</SPAN></B></P></TD><TD width="43%" style="width:43.5%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#FFF2CC;mso-background-themecolor:accent4;mso-background-themetint:
  51;padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">COMPARISON WITH OUR SEQUENCE</SPAN></B></P></TD><TD width="5%" style="width:5.56%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#FFF2CC;mso-background-themecolor:accent4;mso-background-themetint:
  51;padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">Y/N</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:1;height:70.1pt"><TD width="50%" style="width:50.94%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:70.1pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">A single chain insulin agonist analogue with stricture of B-LM-A
  <SPAN class="GramE">wherein</SPAN> B represents an insulin B chain comprising
  the sequence R<SUB>22</SUB>X<SUB>25</SUB>LCGX<SUB>29</SUB></SPAN><SUB><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica;color:black">…</SPAN></SUB><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
  Times;color:black"><SUB> </SUB>and A represents an insulin A chain
  comprising the sequence</SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">GIVX<SUB>4</SUB>X<SUB>5</SUB>CCX<SUB>8</SUB></SPAN><SUB><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica;color:black">…</SPAN></SUB><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
  Times;color:black">-R<SUB>13</SUB></SPAN></P></TD><TD width="43%" style="width:43.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:70.1pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">Both insulin A and B chains involve R groups which stand for
  modifications <SPAN class="SpellE">eg</SPAN>. carboxylation. As our <SPAN class="GramE">insulin</SPAN> B chain does not contain any modifications (except for a substituted glycine on the A chain), our construct is outside the patent</SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:70.1pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">N</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times"><O:P> </O:P></SPAN></P></TD></TR><TR style="mso-yfti-irow:2;height:36.55pt"><TD width="50%" style="width:50.94%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN class="GramE"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
  Times;color:black">Furthermore</SPAN></SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"> the linking moiety linking the <SPAN class="SpellE">carboxy</SPAN>
  terminus of the B chain to the amino terminus of the A chain; further wherein
  the linking moiety is an 8 amino acid sequence comprising of the sequence X<SUB>51</SUB>X<SUB>52</SUB>GSSSX<SUB>57</SUB>X<SUB>58</SUB>
  wherein </SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">X<SUB>51</SUB> = group consisting of glycine, alanine, valine,
  leucine, isoleucine, isoleucine and ornithine </SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">X<SUB>52</SUB> = any amino acid other than tyrosine </SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">X<SUB>57</SUB> and X<SUB>58</SUB> are independently selected
  form the ground consisting of arginine, lysine and ornithine</SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P></TD><TD width="43%" style="width:43.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><I><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black;mso-bidi-font-style:italic">Our amino acid sequence is squarely
  outside the scope of 8 amino acids<I>.</I></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">Even if we did fall within the claim; we do not contain the <SPAN class="GramE">8 amino</SPAN> acid sequence using both potential orientations</SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">X<SUB>51</SUB> is glutamine or arginine in our sequence</SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">B-chain </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
  Helvetica;color:black">–</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;mso-bidi-font-family:Times;color:black"> QR . . . KR </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica;color:black">–</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:
  Times;color:black"> A-chain</SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:36.55pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black;mso-bidi-font-style:italic">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:3;height:52.55pt"><TD width="50%" style="width:50.94%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:52.55pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">The LM also requires the sequence of GAGSSSRR or a sequence that
  differs from GAGSSRR by 1 or 2 amino acids</SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P></TD><TD width="43%" style="width:43.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:52.55pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">Our sequence is 12 amino acids long and differs by more than 4
  amino acids.</SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:52.55pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:4;mso-yfti-lastrow:yes;height:16.25pt"><TD width="50%" style="width:50.94%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">LM represents linking moiety linking the carboxyl terminus of
  the B chain to the amino terminus of <SPAN class="GramE">the a</SPAN> chain,
  wherein said linking moiety is an <SPAN style="mso-bidi-font-weight:bold">8
  amino acid sequence</SPAN> consisting of X<SUB>51</SUB>X<SUB>52</SUB>X<SUB>53</SUB>X<SUB>54</SUB>...
  wherein X<SUB>51</SUB></SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;mso-bidi-font-family:Times;color:black">is selected
  from the group consisting of glycine, alanine, valine, leucine, isoleucine
  and proline</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;
  mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black">…</SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P></TD><TD width="43%" style="width:43.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:16.25pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">Similarly, the patent claim is over an <SPAN class="GramE">8 amino</SPAN>
  acid sequence. Applying the same principle our;</SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">X<SUB>51</SUB> is glutamine or arginine (depending on
  orientation) and outside the scope</SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:16.25pt"><P class="MsoNormal" align="center" style="text-align:center;mso-pagination:none;
  mso-layout-grid-align:none;text-autospace:none"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-bidi-font-family:Times;
  color:black">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_2 box"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:
normal"><SPAN lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">LEE ET
AL.</SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Single Chain Insulin Analog and
a polynucleotide sequence encoding the <SPAN class="SpellE">analog</SPAN></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Patent No: <B style="mso-bidi-font-weight:
normal">US 6,630,348 B1</B></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">October <SPAN class="GramE">7<SUP>th</SUP></SPAN>
2003</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:53.95pt"><TD width="50%" style="width:50.6%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#A1C4C8;padding:0cm 5.4pt 0cm 5.4pt;
  height:53.95pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">CLAIM</SPAN></B></P></TD><TD width="43%" style="width:43.1%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid win
dowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#A1C4C8;padding:0cm 5.4pt 0cm 5.4pt;height:53.95pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">COMPARISON WITH OUR SEQUENCE</SPAN></B></P></TD><TD width="6%" style="width:6.3%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#A1C4C8;padding:0cm 5.4pt 0cm 5.4pt;height:53.95pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">Y/N</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:1"><TD width="50%" style="width:50.6%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">A single chain insulin analogue
  compound of formula (I) having the properties of greater insulin receptor
  binding activity than proinsulin and less insulin receptor binding activity
  than insulin:</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">B chain -<SPAN style="mso-spacerun:yes"> </SPAN>X </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand"> A chain wherein:</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica"><O:P> </O:P></SPAN></P></TD><TD width="43%" style="width:43.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">General B </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"> X </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand"> A chain single chain formula</SPAN></P></TD><TD width="6%" style="width:6.3%;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:accent6;
  mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:2"><TD width="50%" style="width:50.6%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">B and A chain are human
  insulin chains, respectively and,</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="43%" style="width:43.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Our B and A chain are human
  insulin chains although our A chain includes a modification (A21 substitution into
  glycine)</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="6%" style="width:6.3%;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:3;mso-yfti-lastrow:yes;height:79.2pt"><TD width="50%" style="width:50.6%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:79.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">X is a joining peptide of
  about 5 to 18 amino acids comprising the following sequence: <SPAN class="SpellE">Gly</SPAN>-<SPAN class="SpellE">Gly</SPAN>-<SPAN class="SpellE">Gly</SPAN>-Pro-<SPAN class="SpellE">Gly</SPAN>- Lys-<SPAN class="SpellE">Arg</SPAN></SPAN></P></TD><TD width="43%" style="width:43.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:79.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Where the term </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">‘</SPAN><I style="mso-bidi-font-style:
  normal"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">comprising</SPAN></I><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Helvetica;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
  Helvetica">’ </SPAN></I><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:
  Quicksand">is included, the patent requires</SPAN><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand">that the specific sequence named MUST be part
  of the linker region.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Although our sequence is 12
  amino acids long, it does not contain the </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">‘</SPAN><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand">GGGPGLR</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">’</SPAN><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand"> identified in the patent</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica"><O:P> </O:P></SPAN></P></TD><TD width="6%" style="width:6.3%;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:79.2pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_3 box"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:
normal"><SPAN lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">LEE ET
AL.</SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Single Chain Insulin <SPAN class="SpellE">Analogs</SPAN></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Patent No: <B style="mso-bidi-font-weight:
normal">EP 1 193 272 B1</B></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">October <SPAN class="GramE">30<SUP>th</SUP></SPAN>
2004</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:12.75pt"><TD width="48%" style="width:48.28%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#BBB8EB;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">CLAIM</SPAN></B></P></TD><TD width="45%" style="width:45.5%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#BBB8EB;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">COMPARISON WITH OUR SEQUENCE</SPAN></B></P></TD><TD width="6%" style="width:6.22%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#BBB8EB;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">Y/N</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:1;height:12.75pt"><TD width="48%" style="width:48.28%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">A single chain insulin
  analogue compound of formula (I) having the properties of greater insulin
  receptor binding activity than <SPAN class="SpellE">prosinsulin</SPAN> and less
  insulin receptor binding activity than insulin:</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">B Chain </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"> U<SUB>I</SUB></SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"> Z<SUB>n</SUB></SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"> Y </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand"> Z<SUB>I</SUB></SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand"> U<SUB>n </SUB></SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand"> A chain</SPAN></P></TD><TD width="45%" style="width:45.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="6%" style="width:6.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD></TR><TR style="mso-yfti-irow:2;height:14.15pt"><TD width="48%" style="width:48.28%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:14.15pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">B and A chain are human
  insulin chains respectively and</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="45%" style="width:45.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:14.15pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">We have a modified A chain</SPAN></P></TD><TD width="6%" style="width:6.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:14.15pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:3;height:18.35pt"><TD width="48%" style="width:48.28%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:18.35pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">U is an arginine or lysine
  residue</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="45%" style="width:45.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:18.35pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Our </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">‘</SPAN><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand">U</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
  Helvetica">’</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">
  is glutamine</SPAN></P></TD><TD width="6%" style="width:6.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:18.35pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:4;height:27.45pt"><TD width="48%" style="width:48.28%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:27.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Z is a glycine</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="45%" style="width:45.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:27.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Z Is Glycine</SPAN></P></TD><TD width="6%" style="width:6.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:27.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:5;height:12.75pt"><TD width="48%" style="width:48.28%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">I <SPAN class="GramE">is</SPAN>
  an integer of 2 </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:
  Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica">–
  n</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N is an integer of 0 or 2 and</SPAN></P></TD><TD width="45%" style="width:45.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">The maximum size of the linker
  sequence when considering this is 9 amino acids. Since our sequence is 12
  amino acids they are outside the scope</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="6%" style="width:6.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:6;mso-yfti-lastrow:yes;height:58.85pt"><TD width="48%" style="width:48.28%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:58.85pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Y is glycine-<B style="mso-bidi-font-weight:normal">proline-</B>glycine, or alanine-<B style="mso-bidi-font-weight:normal">proline</B>-glycine-aspartic acid</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">–valine, or tyrosine-</SPAN><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand">proline</SPAN></B><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand">-glycine-aspartic acid-valine, or histidine-<B style="mso-bidi-font-weight:normal">proline</B>-glycine-aspartic acid-valine.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="45%" style="width:45.5%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:58.85pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Our sequence has no proline</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="6%" style="width:6.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:58.85pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_4 box"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:
normal"><SPAN lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">KJELDSEN
ET AL.</SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Single Chain insulin</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Patent No:<B style="mso-bidi-font-weight:
normal"> EP 1692168 B1</B></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">December 3<SUP>rd</SUP>, 2004</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:12.75pt"><TD width="48%" style="width:48.82%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#FFF2CC;mso-background-themecolor:accent4;
  mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">CLAIM</SPAN></B></P></TD><TD width="45%" style="width:45.02%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#FFF2CC;mso-background-themecolor:accent4;mso-background-themetint:
  51;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">COMPARISON WITH OUR SEQUENCE</SPAN></B></P></TD><TD width="6%" style="width:6.16%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#FFF2CC;mso-background-themecolor:accent4;mso-background-themetint:
  51;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">Y/N</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:1;height:12.75pt"><TD width="48%" style="width:48.82%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">
  Single-chain insulin for treatment of type 1 diabetes and type 2 diabetes
  having the formula</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN class="GramE"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">B(</SPAN></SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">1-26)- X<SUB>1</SUB>
  - X<SUB>2</SUB> - X<SUB>3</SUB>- X<SUB>4</SUB>- A (1-21),</SPAN></P></TD><TD width="45%" style="width:45.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">B - linker - A formula</SPAN></P></TD><TD width="6%" style="width:6.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:2;height:12.75pt"><TD width="48%" style="width:48.82%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><SPAN class="GramE">B(</SPAN>1-26) is a peptide chain <B style="mso-bidi-font-weight:
  normal">consisting of the first 26 amino acid residues of the B chain of
  human insulin</B> counted from the N-terminal end of the B chain or an
  analogue of the B-chain with one addition or one deletion of one of the amino
  acid residues in the B-chain or derivative of the B-chain being chemically
  modified by introducing a group in the side chain in one or more positions of
  the B-chain or by oxidation or reduction of the side chains of the amino
  acids residues in the B-chain,</SPAN></P></TD><TD width="45%" style="width:45.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">
  Our B chain consists of 28 AA. Although the patents contain different
  versions <SPAN class="SpellE">eg</SPAN></SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">‘</SPAN><SPAN lang="EN-AU" style="font-size:
  14.0pt;font-family:Quicksand">an analogue of the B-chain with one addition or
  deletion</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;
  mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica">’</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"> the total length of the
  B-chain must STILL be 26AA.</SPAN></P></TD><TD width="6%" style="width:6.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:3;height:12.75pt"><TD width="48%" style="width:48.82%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">
  and <SPAN class="GramE">A(</SPAN>1-21) is the natural insulin A chain or an
  analogue thereof with one addition or one deletion of one of the amino acid
  residues in the A-chain or derivative of the A-chain being chemically
  modified by introducing a group in the side chain in one or more positions of
  the A-chain or by oxidation or reduction of the side chains of the amino
  acids residues in the A-chain, wherein</SPAN></P></TD><TD width="45%" style="width:45.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">In our sequence construct </SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">–</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"> the A chain is 21 amino acid however it is a modification of the natural protein. It does not fall within an 'analogue' as there is no complete addition/deletion of an amino acid.</SPAN></P></TD><TD width="6%" style="width:6.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:4;height:12.75pt"><TD width="48%" style="width:48.82%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">
  X<SUB>4 </SUB>does not contain two adjacent basic amino acid residues and
  wherein the single-chain insulin has an affinity to the human insulin
  receptor of at least about 20% of that of human insulin if the single-chain
  insulin molecule is not chemically modified by acylation.</SPAN></P></TD><TD width="45%" style="width:45.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">We have 2 adjacent basic amino
  acid residues and the affinity cannot be tested</SPAN></P></TD><TD width="6%" style="width:6.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:5;height:15.55pt"><TD width="48%" style="width:48.82%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:15.55pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">
  wherein X<SUB>1</SUB> is <SPAN class="SpellE">Thr</SPAN>, Lys or <SPAN class="SpellE">Arg</SPAN></SPAN></P></TD><TD width="45%" style="width:45.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:15.55pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">
  X<SUB>1</SUB> is glutamine</SPAN></P></TD><TD width="6%" style="width:6.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:15.55pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:6;height:12.75pt"><TD width="48%" style="width:48.82%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">
  X<SUB>2</SUB> is Pro, Lys or Asp,</SPAN></P></TD><TD width="45%" style="width:45.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">
  X<SUB>2 </SUB>is arginine</SPAN></P></TD><TD width="6%" style="width:6.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:7;height:12.75pt"><TD width="48%" style="width:48.82%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">
  X<SUB>3</SUB> is Lys, Pro or <SPAN class="SpellE">Glu</SPAN>,</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="45%" style="width:45.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">X<SUB>3</SUB> is glycine</SPAN></P></TD><TD width="6%" style="width:6.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:8;mso-yfti-lastrow:yes;height:12.75pt"><TD width="48%" style="width:48.82%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">X<SUB>4</SUB> is a
  peptide sequence with the following formula <SPAN class="SpellE">X<SUB>a</SUB>-X<SUB>b</SUB>-X<SUB>c</SUB>-X<SUB>d</SUB>-X<SUB>e</SUB>-X<SUB>f</SUB>X<SUB>g</SUB></SPAN> (SEQ
  ID NO:129) wherein</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoListParagraphCxSpFirst" align="center" style="text-align:center"><SPAN class="SpellE"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:
  EN-GB">X<SUB>a</SUB></SPAN></SPAN><SPAN style="font-size:14.0pt;font-family:
  Quicksand;mso-ansi-language:EN-GB"> is selected from the group
  consisting of L, R, T, A, H, Q, G, S and V;</SPAN></P><P class="MsoListParagraphCxSpMiddle" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:EN-GB"><O:P> </O:P></SPAN></P><P class="MsoListParagraphCxSpMiddle" align="center" style="text-align:center"><SPAN class="SpellE"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:
  EN-GB">X<SUB>b</SUB></SPAN></SPAN><SPAN style="font-size:14.0pt;font-family:
  Quicksand;mso-ansi-language:EN-GB"> is selected from the group
  consisting of W, G, S, A, H, R, and T;</SPAN></P><P class="MsoListParagraphCxSpMiddle" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:EN-GB"><O:P> </O:P></SPAN></P><P class="MsoListParagraphCxSpMiddle" align="center" style="text-align:center"><SPAN class="SpellE"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:
  EN-GB">X<SUB>c</SUB></SPAN></SPAN><SPAN style="font-size:14.0pt;font-family:
  Quicksand;mso-ansi-language:EN-GB"> is selected from the group
  consisting of L, Y, M, H, R, T, Q, K, V, S, A, G and P;</SPAN></P><P class="MsoListParagraphCxSpMiddle" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:EN-GB"><O:P> </O:P></SPAN></P><P class="MsoListParagraphCxSpMiddle" align="center" style="text-align:center"><SPAN class="SpellE"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:
  EN-GB">X<SUB>d</SUB></SPAN></SPAN><SPAN style="font-size:14.0pt;font-family:
  Quicksand;mso-ansi-language:EN-GB"> is selected from the group
  consisting of R, A, Y, M, S, N, H, and G;</SPAN></P><P class="MsoListParagraphCxSpMiddle" align="center" style="text-align:center"><SPAN class="SpellE"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:
  EN-GB">X<SUB>e</SUB></SPAN></SPAN><SPAN style="font-size:14.0pt;font-family:
  Quicksand;mso-ansi-language:EN-GB"> is selected from the group
  consisting of S, R, A, T, K, P, N, M, H, Q, V, and G;</SPAN></P><P class="MsoListParagraphCxSpMiddle" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:EN-GB"><O:P> </O:P></SPAN></P><P class="MsoListParagraphCxSpMiddle" align="center" style="text-align:center"><SPAN class="SpellE"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:
  EN-GB">X<SUB>f</SUB></SPAN></SPAN><SPAN style="font-size:14.0pt;font-family:
  Quicksand;mso-ansi-language:EN-GB"> is selected from the group
  consisting of G and A; and</SPAN></P><P class="MsoListParagraphCxSpMiddle" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:EN-GB"><O:P> </O:P></SPAN></P><P class="MsoListParagraphCxSpLast" align="center" style="text-align:center"><SPAN class="SpellE"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-ansi-language:
  EN-GB">X<SUB>g</SUB></SPAN></SPAN><SPAN style="font-size:14.0pt;font-family:
  Quicksand;mso-ansi-language:EN-GB"> is selected from the group
  consisting of K, R, P, H, F, T, I, Q, W, and A,</SPAN></P></TD><TD width="45%" style="width:45.02%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">The total linker length that
  can be formulated from <SPAN class="SpellE">X<SUB>a</SUB></SPAN>– <SPAN class="SpellE">X<SUB>g</SUB></SPAN> is 7 amino acids with the three other
  residues for X<SUB>1</SUB> – X<SUB>3</SUB>. This totals to a maximum linker
  length of 10 amino acids. Our linker is <B style="mso-bidi-font-weight:normal">12
  amino</B> acids long.</SPAN></P></TD><TD width="6%" style="width:6.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_5 box"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:
normal"><SPAN lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">WEISS
ET AL.</SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Fibrillation-resistant insulin
and insulin analogues</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Patent No:<B>EP 2074140 B1</B></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">April 6th, 2009</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:55.45pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#A1C4C8;padding:0cm 5.4pt 0cm 5.4pt;
  height:55.45pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">CLAIM</SPAN></B></P></TD><TD width="46%" style="width:46.08%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#A1C4C8;padding:0cm 5.4pt 0cm 5.4pt;height:55.45pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">COMPARISON WITH OUR SEQUENCE</SPAN></B></P></TD><TD width="6%" style="width:6.18%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#A1C4C8;padding:0cm 5.4pt 0cm 5.4pt;height:55.45pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand">Y/N</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:1;height:86.8pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:86.8pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">An insulin analogue comprising
  a single chain polypeptide containing an insulin A-chain polypeptide and an
  insulin B-chain polypeptide connected by a truncated linker,</SPAN></P></TD><TD width="46%" style="width:46.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:86.8pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Our linker is truncated from
  the entire C-peptide to 12 amino acids and has the general formula of B-X-A
  where our linker is</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">QRGGGSGGGQKR</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="6%" rowspan="2" style="width:6.18%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:86.8pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:2;height:8.6pt"><TD width="93%" colspan="2" style="width:93.82%;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:8.6pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">wherein the truncated linker
  is a polypeptide selected from the group consisting of:</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD></TR><TR style="mso-yfti-irow:3;height:12.05pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">a polypeptide having the
  sequence GGGPRR</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">No proline</SPAN></P></TD><TD width="6%" style="width:6.18%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:4;height:12.75pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">a polypeptide having the
  sequence GGPRR</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">No proline</SPAN></P></TD><TD width="6%" style="width:6.18%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:5;height:5.05pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:5.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">a polypeptide having the
  sequence GSEQRR</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:5.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">No glutamate</SPAN></P></TD><TD width="6%" style="width:6.18%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:5.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:6;height:12.75pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">a polypeptide having the
  sequence RREQR</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">No glutamate</SPAN></P></TD><TD width="6%" style="width:6.18%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:7;height:12.75pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">a polypeptide having the
  sequence RREALQKR</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">No glutamate</SPAN></P></TD><TD width="6%" style="width:6.18%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:8;height:27.45pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:27.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">a polypeptide having the
  sequence GAGPRR</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:27.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">No proline</SPAN></P></TD><TD width="6%" style="width:6.18%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:27.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:9;height:12.75pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">a polypeptide having the
  sequence GPRR</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">No proline</SPAN></P></TD><TD width="6%" style="width:6.18%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:10;height:30.95pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:30.95pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">wherein the insulin B-chain
  polypeptide optionally contains one or more of:</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">an aspartate substitution at
  the position corresponding to position B10 of insulin,</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">a lysine or an aspartate
  substitution at the position corresponding to position B28 of insulin, and</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">a proline substitution at the
  position corresponding to position B29 of insulin</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:30.95pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Our B-chain is native human
  insulin</SPAN></P></TD><TD width="6%" style="width:6.18%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:30.95pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:11;mso-yfti-lastrow:yes;height:12.75pt"><TD width="47%" style="width:47.74%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">
  and wherein the insulin A-chain polypeptide contains a histidine substitution
  at the position corresponding to position A8 of insulin.</SPAN></P></TD><TD width="46%" style="width:46.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Our A-chain does not contain
  the relevant substitution</SPAN></P></TD><TD width="6%" style="width:6.18%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_6 box"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:
normal"><SPAN lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">STOWELL
ET AL.</SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Chemically and thermodynamically
stable insulin analogues and improved</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">methods for their production</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">Patent No: <B style="mso-bidi-font-weight:
bold">US 9006176 B2</B></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:16.0pt;font-family:Quicksand">October <SPAN class="GramE">16<SUP>th</SUP></SPAN>
2012</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:14.85pt"><TD width="48%" style="width:48.32%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#BBB8EB;padding:0cm 5.4pt 0cm 5.4pt;
  height:14.85pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:15.0pt;font-family:Quicksand">CLAIM</SPAN></P></TD><TD width="45%" style="width:45.14%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#BBB8EB;padding:0cm 5.4pt 0cm 5.4pt;height:14.85pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR SEQUENCE</SPAN></P></TD><TD width="6%" style="width:6.54%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#BBB8EB;padding:0cm 5.4pt 0cm 5.4pt;height:14.85pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:bold"><SPAN lang="EN-AU" style="font-size:15.0pt;
  font-family:Quicksand"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:15.0pt;font-family:Quicksand">Y/N</SPAN></P></TD></TR><TR style="mso-yfti-irow:1;height:12.75pt"><TD width="48%" style="width:48.32%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">A single chain insulin (SCI)
  compound of formula a(I):</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">B chain - C</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">’</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"> – A Chain (Formula (I))</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">having the properties of
  higher affinity for the insulin receptor and lower affinity for the IGF-1
  receptor as compared to those of native proinsulin with chemical and
  thermodynamic degradation profiles such that the SCI can be formulated and
  stored for extended periods of time without refrigeration;</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="45%" style="width:45.14%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Correct linker formulation of
  B-linker-A</SPAN></P></TD><TD width="6%" style="width:6.54%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:2;height:12.75pt"><TD width="48%" style="width:48.32%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">W herein B chain and A chain
  are modified human insulin chains; and</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="45%" style="width:45.14%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Only the A chain is modified<O:P> </O:P></SPAN></P></TD><TD width="6%" style="width:6.54%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:3;height:12.75pt"><TD width="48%" style="width:48.32%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">Wherein C</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">’</SPAN><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"> covalently links the
  C-terminus of the B chain to the N-terminus of the A chain, and is a peptide
  of 5 amino acids comprising the following sequence: Y-P-G-D-X (SEQ ID NO: 1);
  wherein X is any amino acid;</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="45%" style="width:45.14%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">No proline (P) and no aspartic
  acid (D)</SPAN></P></TD><TD width="6%" style="width:6.54%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:4;mso-yfti-lastrow:yes;height:12.75pt"><TD width="48%" style="width:48.32%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">wherein the B chain is
  modified from a native human insulin B chain (SEQ ID NO:11), and A chain is
  modified from a native human insulin A chain (SEQ ID NO:10), wherein the
  modifications comprise one or more mutations at</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">(1) Gln5, Gln15, Asn18, or
  Asn21 of SEQ ID NO:10, or</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">(2) Asn3 or Gln5 of SEQ ID
  NO:11; resulting in enhanced resistance to <SPAN class="SpellE">deamidation</SPAN>.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="45%" style="width:45.14%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">B is not modified and A chain
  does not have similar modifications, rather an addition at residue 1 without
  the purpose of resisting deamination.</SPAN></P></TD><TD width="6%" style="width:6.54%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#FFC8CD;padding:0cm 5.4pt 0cm 5.4pt;
  height:12.75pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV></DIV></DIV><DIV class="row"><DIV class="content" id="please"><CENTER><H1><B>2.</B> Method Patents</H1></CENTER><H4><CENTER>In looking at patents, we first considered looking at different methods of production – particularly whether or not Bacillus secretory methods are patented for insulin production. From a preliminary search, Bacillus secretion has been previously patented however most are now expired. If it is possible to find a patent using the same method of production as a previously patented product, it will not infringe anyone elses intellectual property.</CENTER></H4></DIV></DIV><DIV class="row"><DIV class="content" id="please"><DIV class="choose box12"><H4> relatively important PATENT STUFF</H4></DIV><DIV class="patent_10 box12"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:20.0pt;font-family:Quicksand">STAHL ET AL.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">Method for Producing
Heterologous Proteins</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">Patent No: US4801536A</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">November 10th, 1985</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:20.0pt;font-family:Quicksand">STAHL ET AL.</SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:15.55pt"><TD width="49%" style="width:49.86%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;
  height:15.55pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">CLAIMS</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="44%" style="width:44.72%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;height:15.55pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR METHOD</SPAN></P></TD><TD width="5%" style="width:5.42%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;height:15.55pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">Y/N</SPAN></P></TD></TR><TR style="mso-yfti-irow:1;height:33.0pt"><TD width="94%" colspan="2" style="width:94.58%;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:33.0pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Status: EXPIRED. Now this
  patent has expired. Importantly </SPAN><SPAN style="font-size:14.0pt;
  font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
  Helvetica">–</SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand"> it
  covers our 
  project as we have a heterologous protein being attached via a secretion tag
  to the actual plasmid vector design.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.42%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:33.0pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:2"><TD width="49%" style="width:49.86%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">A method for producing a
  heterologous protein in a bacterial host cell such that the protein is
  exported from the host cell into the culture medium, the method comprising
  culturing in a bacterial culture medium a genetically engineered bacterial
  strain containing a fusion DNA sequence which comprises a first nucleotide
  sequence encoding at least an N-terminal portion of a <SPAN class="SpellE">flagellin</SPAN>
  protein native to the bacterial host cell species and a second nucleotide
  sequence encoding the heterologous protein, said first nucleotide sequence
  being linked via its 3' terminus to the 5' terminus of the second DNA
  sequence and said fusion DNA sequence being operatively linked to an
  expression control sequence and wherein said N-terminal portion results in
  the export of said heterologous protein.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="44%" style="width:44.72%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Our plasmid falls directly
  into this means of production. As this patent has since expired and we fall
  under it </SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand;
  mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica">– the
  methods that are encoded are free to be used and thus not for law suit.</SPAN></P></TD><TD width="5%" style="width:5.42%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:3"><TD width="49%" style="width:49.86%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">A plasmid as identified in any
  of Tables 2 to 5 of the specification by the designation <SPAN class="SpellE">pSPA</SPAN>
  or <SPAN class="SpellE">pSPB</SPAN>.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="44%" style="width:44.72%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">WB800 plasmid</SPAN></P></TD><TD width="5%" style="width:5.42%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:4;mso-yfti-lastrow:yes;height:60.3pt"><TD width="49%" style="width:49.86%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:60.3pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">A DNA sequence flanked by and
  in proper reading frame with a non-wild type open reading frame encoding a
  secretory signal sequence having the amino acid sequence: pSPB4, pSPB9,
  pSPB19, pSPB20, pSPB23, pSPB28</SPAN></P></TD><TD width="44%" style="width:44.72%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:60.3pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">None of the plasmids mentioned
  are being used nor are the AA sequences that are described in greater detail
  in the patent</SPAN></P></TD><TD width="5%" style="width:5.42%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:60.3pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_11 box12"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:20.0pt;font-family:Quicksand">KOVACEVIC ET AL.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">Method for expression and
secretion in Bacillus</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">Patent No: US5032510A</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">July 16th, 1991</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:30.25pt"><TD width="48%" style="width:48.22%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt;
  height:30.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">CLAIMS</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.22%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR METHOD</SPAN></P></TD><TD width="5%" style="width:5.56%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">Y/N</SPAN></P></TD></TR><TR style="mso-yfti-irow:1;height:30.25pt"><TD width="94%" colspan="2" style="width:94.44%;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">STATUS: Expired. The invention
  method claimed is now open source.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:2;height:30.25pt"><TD width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt"><P class="MsoNormal"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">1. A method for expressing a
  peptide in Bacillus, said method comprising </SPAN></P></TD><TD width="46%" style="width:46.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt"><P class="MsoNormal"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">We are expressing a
  peptide/polypeptide in Bacillus</SPAN></P><P class="MsoNormal"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:30.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:3"><TD width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">a) transforming a Bacillus
  host cell which is rendered competent for transformation with a recombinant
  DNA expression vector which is selectable and capable of replication in said
  host cell, said vector comprising </SPAN></P></TD><TD width="46%" style="width:46.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Our Bacillus host cell was
  made competent specifically for recombinant DNA uptake. The expression vector
  is also capable of replication</SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:4"><TD width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">1) the transcriptional and
  translational activating sequence of the Staphylococcus aureus nuclease gene
  and</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">2) a cloned DNA sequence that
  codes for a polypeptide, and</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">This vector however does not
  include a Staph. Aureus nuclease gene.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN class="SpellE"><SPAN style="font-size:14.0pt;font-family:Quicksand">Winsulin</SPAN></SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand"> is a single poly-peptide
  chain, while Insulin is a dual-peptide complex</SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:5;mso-yfti-lastrow:yes;height:146.25pt"><TD width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:146.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">b) culturing said transformed
  cell under conditions suitable for expression of said polypeptide, subject to
  the limitation 1) that said cloned DNA sequence that codes for said
  polypeptide and said transcriptional and translational activating sequence
  are immediately adjacent, in translational reading frame and positioned for
  expression of said polypeptide and 2) that said cloned DNA sequence that
  codes for said polypeptide is exclusive of the nucleotide triplet that codes
  for the N-terminal amino acid of said polypeptide when said amino acid is
  methionine.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:146.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">This potentially could be an
  issue, depending on the reading and interpretation. However, since we fall
  outside of the above key aspects of this individual claim, we are still in
  the clear.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:146.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_12 box12"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:20.0pt;font-family:Quicksand">BERKA ET AL.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">Heterologous polypeptide
expressed in filamentous fungi, processes for their preparation, and vectors
for their preparation</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">Patent No: EP0369817B1</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">April 24th, 1996</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:14.85pt"><TD width="48%" style="width:48.22%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#E8939C;padding:0cm 5.4pt 0cm 5.4pt;
  height:14.85pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">CLAIMS</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.22%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#E8939C;padding:0cm 5.4pt 0cm 5.4pt;height:14.85pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR METHOD</SPAN></P></TD><TD width="5%" style="width:5.56%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#E8939C;padding:0cm 5.4pt 0cm 5.4pt;height:14.85pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">Y/N</SPAN></P></TD></TR><TR style="mso-yfti-irow:1;height:86.85pt"><TD width="94%" colspan="2" style="width:94.44%;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:86.85pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Status: EXPIRED</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">The expiry date of this patent
  is extremely critical as it patents the production of proteins in a Bacillus
  cell with multiple gene knockouts. Importantly, the strain used by us, WB800
  contains 8 protease knockouts and thus falls within the scope of this patent.
  As the patent has expired </SPAN><SPAN style="font-size:14.0pt;font-family:
  Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica">–this
  means of production is available for use.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:86.85pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:2;height:197.25pt"><TD width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:197.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Claim 1</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">A Bacillus cell
  characterised in containing a mutation in the <SPAN class="SpellE">epr</SPAN> gene,
  said <SPAN class="SpellE">epr</SPAN> gene encoding a protein
  comprising the amino acid sequence of Figure 6 or an evolutionary homologue
  thereof of other Bacillus species, having protease activity, said
  mutation resulting in inhibition of the production by said cell of <SPAN class="SpellE">proteolytically</SPAN> active <SPAN class="SpellE">epr</SPAN> gene
  product.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:197.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">We have a mutation in the <SPAN class="SpellE">epr</SPAN> gene in WB800, which renders the EPR protein inactive
  such that it does not have a <SPAN class="SpellE">proteolytically</SPAN> active
  <SPAN class="SpellE">epr</SPAN> gene product</SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt;height:197.25pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR><TR style="mso-yfti-irow:3;mso-yfti-lastrow:yes"><TD width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Claim 16</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">A method for producing a
  heterologous polypeptide in a Bacillus cell, characterised in
  comprising: introducing into said cell a gene encoding said heterologous
  polypeptide, modified to be expressed in said cell,
  said Bacillus cell containing mutations in the <SPAN class="SpellE">apr</SPAN> and <SPAN class="SpellE">npr</SPAN> genes,
  and further containing mutations in one or more of the genes encoding the <SPAN class="SpellE">Epr</SPAN> protease, RP-I, or RP-II, said <SPAN class="SpellE">Epr</SPAN>,
  RP-I and RP-II comprising the amino acid sequences set out in Figures 6, 10
  and 14 respectively, or evolutionary homologues thereof of
  other Bacillus species, having protease activity, wherein said
  mutation results in the inhibition of the production by said cell of <SPAN class="SpellE">proteolytically</SPAN> active <SPAN class="SpellE">Epr</SPAN>
  protease, RP-I or RP-II.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.22%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">We have a mutation in <SPAN class="SpellE">aprE</SPAN> and <SPAN class="SpellE">nprE</SPAN><SPAN class="GramE">and also</SPAN><SPAN class="SpellE">epr</SPAN> and thus fall
  within this claim.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.56%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#E2EFD9;mso-background-themecolor:
  accent6;mso-background-themetint:51;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Y</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_13 box12"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:20.0pt;font-family:Quicksand">WIDNER ET AL.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">Methods for producing a
polypeptide in a Bacillus cell</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">Patent No: US6255076B1</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">July 3rd, 2001</SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes"><TD width="47%" style="width:47.72%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">CLAIMS</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.84%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR METHOD</SPAN></P></TD><TD width="5%" style="width:5.44%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">Y/N</SPAN></P></TD></TR><TR style="mso-yfti-irow:1"><TD width="47%" style="width:47.72%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoListParagraphCxSpFirst" align="center" style="text-align:center;
  text-indent:-18.0pt;mso-list:l0 level1 lfo1"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Quicksand;
  mso-bidi-font-family:Quicksand"><SPAN style="mso-list:Ignore">1.<SPAN style="font:7.0pt &quot;Times New Roman&quot;">    </SPAN></SPAN></SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand">A method for producing a
  polypeptide, comprising:</SPAN></P><P class="MsoListParagraphCxSpLast" align="center" style="text-align:center;
  text-indent:-18.0pt;mso-list:l0 level1 lfo1"><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Quicksand;
  mso-bidi-font-family:Quicksand"><SPAN style="mso-list:Ignore">2.<SPAN style="font:7.0pt &quot;Times New Roman&quot;">   </SPAN></SPAN></SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">(a) cultivating
  a Bacillus cell in a medium conducive for the production of the
  polypeptide, wherein the Bacillus cell comprises a nucleic acid
  construct comprising a tandem promoter in which each promoter sequence of the
  tandem promoter is operably linked to a nucleic acid sequence encoding the
  polypeptide, wherein the tandem promoter comprises promoters selected from
  the group consisting of the <SPAN class="SpellE">amyL</SPAN> promoter, <SPAN class="SpellE">amyQ</SPAN> promoter, <SPAN class="SpellE">aprH</SPAN> promoter, <SPAN class="SpellE">cryIIIA</SPAN> promoter, <SPAN class="SpellE">subtilisin</SPAN>
  Carlsberg gene promoter, and consensus promoters of the <SPAN class="SpellE">amyL</SPAN>
  promoter, <SPAN class="SpellE">amyQ</SPAN> promoter, <SPAN class="SpellE">aprH</SPAN>
  promoter, <SPAN class="SpellE">cryIIIA</SPAN> promoter, and <SPAN class="SpellE">subtilisin</SPAN>
  Carlsberg gene promoter having the sequence TTGACA for the </SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">“</SPAN><SPAN style="font-size:14.0pt;
  font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
  Calibri">_</SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand;
  mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica">35” region
  and TATAAT for the “</SPAN><SPAN style="font-size:14.0pt;font-family:Calibri;
  mso-fareast-font-family:Calibri;mso-bidi-font-family:Calibri">_</SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">10” region; and</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">(b) isolating the polypeptide
  from the cultivation medium.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.84%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">We do not have a tandem
  promoter <SPAN class="GramE">series,</SPAN> therefore we fall outside of this
  claim.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">We are also using the </SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">… promoter, which is not listed there.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">We will be cultivating the
  medium for polypeptide isolation however.</SPAN></P></TD><TD width="5%" style="width:5.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:2;mso-yfti-lastrow:yes;height:112.05pt"><TD width="47%" style="width:47.72%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:112.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">11. A method for producing a
  polypeptide, comprising:</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">(a) cultivating
  a Bacillus cell in a medium conducive <SPAN class="GramE">for the
  production of</SPAN> the polypeptide, wherein the Bacillus cell
  comprises a nucleic acid construct comprising</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">(<SPAN class="SpellE">i</SPAN>)
  a consensus promoter obtained from Bacillus <SPAN class="SpellE">amyloliquefaciens</SPAN> alpha-amylase
  gene (<SPAN class="SpellE">amy</SPAN> Q)
  or Bacillus subtilis alpha-amylase gene (<SPAN class="SpellE">amy</SPAN>
  E) having the sequence TTGACA for the </SPAN><SPAN style="font-size:14.0pt;
  font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
  Helvetica">“</SPAN><SPAN style="font-size:14.0pt;font-family:Calibri;
  mso-fareast-font-family:Calibri;mso-bidi-font-family:Calibri">_</SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">35” region and TATAAT for the “</SPAN><SPAN style="font-size:14.0pt;font-family:Calibri;mso-fareast-font-family:Calibri;
  mso-bidi-font-family:Calibri">_</SPAN><SPAN style="font-size:14.0pt;
  font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
  Helvetica">10” region operably linked to a single copy of a nucleic acid
  sequence encoding the polypeptide and</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">(ii) an mRNA
  processing/stabilizing sequence located downstream of the consensus promoter
  and upstream of the nucleic acid sequence encoding the polypeptide; and</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">(b) isolating the polypeptide
  from the cultivation medium.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.84%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:112.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Arguable </SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">– how to define whether</SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand"> the medium we will use will
  be </SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica">‘conductive’ or not is vague.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">We are not using a consensus
  promoter from Bacillus <SPAN class="SpellE">amyloliquefaciens</SPAN>, but are
  using the Bacillus subtilis strain. The promoter we have selected is p-<SPAN class="SpellE">Spac</SPAN></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">We also do not have an mRNA
  processing or stabilising sequence in our <SPAN class="SpellE">gblock</SPAN>.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">We are isolating our
  polypeptide from the cultivation medium.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:112.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_14 box12"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:20.0pt;font-family:Quicksand">BEDZYK ET AL.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">Natural promoters for gene
expression and metabolic monitoring in Bacillus species</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">Patent No: EP1294909 A2</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:16.0pt;font-family:Quicksand">June 29th, 2001</SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:7.95pt"><TD width="48%" style="width:48.22%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;
  height:7.95pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">CLAIMS</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.34%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;height:7.95pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">COMPARISON WITH OUR METHOD</SPAN></P></TD><TD width="5%" style="width:5.44%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;height:7.95pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:15.0pt;font-family:Quicksand">Y/N</SPAN></P></TD></TR><TR style="mso-yfti-irow:1;height:21.9pt"><TD width="94%" colspan="2" style="width:94.56%;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:21.9pt"><P class="MsoNormal" align="center" style="text-align:center"><U><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P><SPAN style="text-decoration:
   none"> </SPAN></O:P></SPAN></U></P><P class="MsoNormal" align="center" style="text-align:center"><U><SPAN style="font-size:14.0pt;font-family:Quicksand">Legal Status</SPAN></U><SPAN style="font-size:14.0pt;font-family:Quicksand">: abandoned patent</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Once a patent is abandoned it
  does not have any effect.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:21.9pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:2;mso-yfti-lastrow:yes;height:47.05pt"><TD width="48%" style="width:48.22%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:47.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">A method for the expression of
  a coding region of interest in a Bacillus <SPAN class="SpellE">sp</SPAN>
  comprising:</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">a) providing a transformed
  Bacillus <SPAN class="SpellE">sp</SPAN> cell having a chimeric gene comprising
  a nucleic acid fragment comprising the promoter region of a Bacillus gene
  operably linked to a coding region of interest expressible in a Bacillus <SPAN class="SpellE">sp</SPAN>, wherein the nucleic acid fragment comprising the
  promoter region of a Bacillus gene is selected from the group consisting of <SPAN class="SpellE">narGHJT</SPAN>, <SPAN class="SpellE">csn</SPAN>, <SPAN class="SpellE">yncM</SPAN>, <SPAN class="SpellE">yvyD</SPAN>, <SPAN class="SpellE">yvaWXY</SPAN>,
  <SPAN class="SpellE">ydjL</SPAN>, <SPAN class="SpellE">sunA</SPAN>, and <SPAN class="SpellE">yolIJK</SPAN> and homologues thereof; and</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">b) growing the transformed
  Bacillus <SPAN class="SpellE">sp</SPAN> cell of step (a) in the absence of
  oxygen wherein the chimeric gene of step (a) is expressed.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P></TD><TD width="46%" style="width:46.34%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:47.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">Although we do use the <SPAN class="SpellE">yncM</SPAN> tag mentioned in this patent </SPAN><SPAN style="font-size:14.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;
  mso-bidi-font-family:Helvetica">– however their use of <SPAN class="SpellE">YncM</SPAN>
  is as a nucleic acid fragment in the promoter region which is distinct from
  our purpose.</SPAN></P></TD><TD width="5%" style="width:5.44%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:47.05pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN style="font-size:14.0pt;font-family:Quicksand">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV></DIV></DIV><DIV class="row"><DIV class="content" id="please"><CENTER><H1><B>3.</B> Orange Book/FDA</H1></CENTER><H4><CENTER>We also considered patents without single chain insulin to identify whether existing commercial / FDA products involved patented methods eg. storage etc., that may be broad enough to include insulin analogues like Winsulin. Looking through the Orange Book, a drug database showing all products that have been approved -  including their therapeutic equivalences, our team searched through all 101 entries that involved insulin to determine whether or not we would fall under a patent here.</CENTER></H4></DIV></DIV><DIV class="row" id="nav3"><DIV class="content" id="please"><CENTER><H1>Search Method</H1></CENTER><DIV class="row"><DIV class="col-xs-6"><DIV align="center"><H4>All 101 patents were collated it in an excel data table (right: <U>screenshot of excel data sheet</U>) and formatted with Y/N based on their expiry date. We then picked out all the patents (<I>green</I>) in force and ordered them by their relevant associated patents and their associated claims.
</H4><H3>Patent Categories</H3><H4>1.	Sequence 
2.	Device 
3.	Preparation / Storage
Interestingly, most of the patents for insulin that are still in force, surround the physical devices which are used to inject the insulin eg. automatic injection devices, or alternatively means of storage. This is unsurprising as insulin as a therapeutic has been around for over 50 years. 
</H4></DIV></DIV></DIV><DIV class="row"><DIV class="choose box10">Click for different patent classes!</DIV><DIV class="patent_20 box10"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">SEQUENCE</SPAN></P><P class="MsoNormal"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 &lt;tbody&gt;&lt;tr style=" mso-yfti-irow:0=""><TBODY><TR><TD style="border:solid windowtext 1.0pt;mso-border-alt:solid windowtext .5pt;
  background:#FAD990;padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">PRODUCT NAME</SPAN></B></P></TD><TD style="border:solid windowtext 1.0pt;border-left:none;mso-border-left-alt:
  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;background:#FAD990;
  padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">PRODUCT CODE</SPAN></B></P></TD><TD style="border:solid windowtext 1.0pt;border-left:none;mso-border-left-alt:
  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;background:#FAD990;
  padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">PATENTS</SPAN></B></P></TD><TD style="border:solid windowtext 1.0pt;border-left:none;mso-border-left-alt:
  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;background:#FAD990;
  padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">NATURE OF CLAIM /
  JUSTIFICATION OF DIFFERENCE</SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></B></P></TD><TD style="border:solid windowtext 1.0pt;border-left:none;mso-border-left-alt:
  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;background:#FAD990;
  padding:0cm 5.4pt 0cm 5.4pt;height:36.55pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">Y/N</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:1;height:40.7pt"><TD style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:40.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN ASPART; INSULIN DEGLUDEC (RYZOGDEG 70/30)</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N203313</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">5866538</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">The sequence claimed in this patent consists
  of Asp(B28) human insulin which we don’t have. Furthermore, it involves the
  actual preparation of the “insulin with glycerol and or mannitol and 5-100mM
  of a halogen, including chloride and specifically <SPAN class="SpellE">NaCl</SPAN>.”</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">Whilst these are not relevant to us in the
  present stages of our projects – they have implications on how we plan to
  store the insulin in the future</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD></TR><TR style="mso-yfti-irow:2"><TD style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">INSULIN DEGLUDEC</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">(TRESIBA)</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N203314</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">7615532</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;color:black;mso-themecolor:text1;mso-bidi-font-weight:
  bold"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  mso-bidi-font-family:Arial;color:black;mso-themecolor:text1;mso-bidi-font-weight:
  bold">The sequence claimed by this patent involves a 4-amino acid linker
  which notable involves carboxylation of at least one of the amino acids
  present</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><B><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:
  &quot;Times New Roman&quot;;mso-bidi-font-family:Arial;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></B></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:3"><TD style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN DEGLUDEC, LIRAGLUTIDE (XULTOPHY 100/3.6)</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N208583</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">6268343, 6458924, 7235627, 8937042</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">The present claim involves a GLP-1 compound
  with an insulin peptide. GLP-1’s <SPAN class="GramE">are</SPAN> regulatory <SPAN class="SpellE">insulintoprohic</SPAN> compounds which are administered together
  with insulin in this pharmaceutical product. Importantly, the insulin used is
  <SPAN class="SpellE">carboxylated</SPAN> and with additional modifications;
  sequence is </SPAN><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;
  mso-fareast-font-family:Helvetica;mso-bidi-font-family:Helvetica;color:black;
  mso-themecolor:text1">N</SPAN><SPAN lang="EN-AU" style="font-size:13.0pt;
  mso-ascii-font-family:Calibri;mso-fareast-font-family:Calibri;mso-hansi-font-family:
  Calibri;mso-bidi-font-family:Calibri;color:black;mso-themecolor:text1">_</SPAN><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:
  Helvetica;mso-bidi-font-family:Helvetica;color:black;mso-themecolor:text1">B29-(N</SPAN><SPAN lang="EN-AU" style="font-size:13.0pt;mso-ascii-font-family:Calibri;mso-fareast-font-family:
  Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri;
  color:black;mso-themecolor:text1">_</SPAN><SPAN lang="EN-AU" style="font-size:
  13.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
  Helvetica;color:black;mso-themecolor:text1">-(COOH(CH2)14CO)-</SPAN><SPAN lang="EN-AU" style="font-size:13.0pt;mso-ascii-font-family:Calibri;mso-fareast-font-family:
  Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri;
  color:black;mso-themecolor:text1">_</SPAN><SPAN lang="EN-AU" style="font-size:
  13.0pt;font-family:Quicksand;mso-fareast-font-family:Helvetica;mso-bidi-font-family:
  Helvetica;color:black;mso-themecolor:text1">-<SPAN class="SpellE"><SPAN class="GramE">Glu</SPAN></SPAN><SPAN class="GramE">)desB</SPAN>30)</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:4;height:10.7pt"><TD style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN DETEMIR RECOMBINANT (LEVEMINR / LEVIMER FLEXTOUCH)</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N023156</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">5750497</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN class="SpellE"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">Acylated</SPAN></I></SPAN><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"> insulin</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">The sequence claimed involve <SPAN class="SpellE">acylated</SPAN><SPAN class="SpellE">produts</SPAN> and do not reference to single chain insulin
  production. These <SPAN class="SpellE">acylations</SPAN> are additional to
  other modifications to the A and B chains including sequence deletions and
  substitutions which are not present in our sequence. This includes <SPAN class="SpellE">Gly</SPAN>(A21), <SPAN class="SpellE">Arg</SPAN> (b31), <SPAN class="SpellE">Arg</SPAN>(B32)-human insulin.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:5;height:20.45pt"><TD style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:20.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN GLARGINE; LIXISENATIDE (SOLIQUA 100/33)</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N205692</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">9345750</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Long-acting formulations of insulins</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">The insulin formulation that is covered is
  specifically insulin glargine at a specific amount (300 U/mL) and <SPAN class="SpellE">not</SPAN> other compounds</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:6;mso-yfti-lastrow:yes;height:10.7pt"><TD style="border:solid windowtext 1.0pt;border-top:none;mso-border-top-alt:
  solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN GLARGINE RECOMBINANT (APIDRA)</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N021629</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">6221633</SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Novel insulin derivatives with rapid onset of action</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">We are still squarely out of this. The primary modifications allowed
  by this patent are human and animal insulin substitutions. However, In Claim
  2 - B30 is a -OH or the amino acid residue and furthermore, B1 is a
  phenylalanine residue or a hydrogen atom and B3 is a basic amino acid.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">These do NOT cover human insulin single chains</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD style="border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;mso-border-top-alt:solid windowtext .5pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_21 box10"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">DEVICE</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes"><TD width="19%" style="width:19.76%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">PRODUCT NAME</SPAN></B></P></TD><TD width="11%" style="width:11.9%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">PRODUCT CODE</SPAN></B></P></TD><TD width="11%" style="width:11.9%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">PATENTS</SPAN></B></P></TD><TD width="51%" style="width:51.28%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">NATURE OF CLAIM /
  JUSTIFICATION OF DIFFERENCE</SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD width="5%" style="width:5.16%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#93BCC1;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">Y/N</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:1"><TD width="19%" rowspan="5" style="width:19.76%;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">INSULIN DEGLUDEC</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">(TRESIBA)</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P></TD><TD width="11%" rowspan="5" style="width:11.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N203314</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">6899699, 947154</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Automatic injection device with reset feature</SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:2"><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">8672898,</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">9687611</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">An automatic injection device with a top release
  mechanism</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:3;height:26.7pt"><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:26.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">8684969, 9486588</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:26.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Injection device that houses torsion springs and
  rotatable display influencing the operative manner of dosing insulin</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:26.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:4"><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">8920383, 9132239</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Dose mechanism for an injection device for limiting a
  dose setting corresponding to the amount of medicament left</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:5"><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">9108002</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Dial down mechanism for wind-up type pens</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:6"><TD width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN DEGLUDEC, LIRAGLUTIDE (XULTOPHY 100/3.6)</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N208583</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">6899699, 8672898, 8684969, 9108002,
  9132239, 9457154, 9486588, 9687611</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Automatic injection device with reset feature</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:7;height:10.7pt"><TD width="19%" rowspan="2" style="width:19.76%;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN GLARGINE RECOMBINANT (LANTUS/LANTUS SOLOSTAR)</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="11%" rowspan="2" style="width:11.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N021080</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">7918833</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Pen-type injector with dose dial sleeve</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:8;height:10.7pt"><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">7918833</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Pen-type injector with dose dial sleeve</SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:9;height:10.7pt"><TD width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN GLARGINE RECOMBINANT (TOUJEO SOLOSTAR)</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N206538</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">7918833</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Pen-type injector with dose dial sleeve</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:10;height:20.45pt"><TD width="19%" rowspan="2" style="width:19.76%;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN GLARGINE; LIXISENATIDE (SOLIQUA 100/33)</SPAN></P></TD><TD width="11%" rowspan="2" style="width:11.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N205692</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">8512297</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:20.45pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Drive mechanisms suitable for use in drug delivery
  devices</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:20.45pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:11;height:10.7pt"><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">8556864, 8603044, 8679069, 8992486,
  9011391, 9233211, 9408979, 9526844,</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">9533105,</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">9561331, 9604008, 9604009, 9610409, 9623189,
  9775954</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">Pen-type injector with dose dial sleeve</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:12;height:10.7pt"><TD width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN HUMAN (HUMULIN R, HUMULIN R PEN, HUMULUN 70/30, HUMULIN 70/30/
  PEN)</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N018780</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">7291132</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Medication dispensing apparatus with triple screw
  threads for mechanical advantage</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:13;height:10.7pt"><TD width="19%" rowspan="2" style="width:19.76%;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN LISPRO RECOMBINANT (HUMALOG KWIPEN)</SPAN></P></TD><TD width="11%" rowspan="2" style="width:11.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N2057479</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">7291132</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Medication dispensing apparatus with triple screw
  threads for mechanical advantage</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:14;mso-yfti-lastrow:yes;height:10.7pt"><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">6551992</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">Biosynthetic osteogenic proteins and
  osteogenic devices containing them</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">both devices and the actual materials - these materials have a
  specific sequence and conformation to induce endochondral bone formation when
  disposed within a matrix. Own insulin is not synthesised to have that purpose
  and although it does have six cysteine residues – the patent covers a very specific
  sequence that is longer than our product. <SPAN class="GramE">Furthermore</SPAN>
  this patent is only relevant to a pair of polypeptides which is unlikely our
  single chain, <SPAN class="SpellE">Winsulin</SPAN>.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:14.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV><DIV class="patent_22 box10"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">PREPARATION / STORAGE</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-family:Quicksand"><O:P> </O:P></SPAN></P><DIV style="overflow-x:auto;"><TABLE class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" width="100%" style="width:100.0%;border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-yfti-tbllook:1184;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"><TBODY><TR style="mso-yfti-irow:0;mso-yfti-firstrow:yes;height:26.1pt"><TD width="19%" style="width:19.76%;border:solid windowtext 1.0pt;mso-border-alt:
  solid windowtext .5pt;background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt;
  height:26.1pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">PRODUCT NAME</SPAN></B></P></TD><TD width="11%" style="width:11.9%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt;height:26.1pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">PRODUCT CODE</SPAN></B></P></TD><TD width="11%" style="width:11.9%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt;height:26.1pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">PATENTS</SPAN></B></P></TD><TD width="51%" style="width:51.28%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt;height:26.1pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">NATURE OF CLAIM /
  JUSTIFICATION OF DIFFERENCE</SPAN></B></P><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></B></P></TD><TD width="5%" style="width:5.16%;border:solid windowtext 1.0pt;border-left:
  none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  background:#9EA6EA;padding:0cm 5.4pt 0cm 5.4pt;height:26.1pt"><P class="MsoNormal" align="center" style="text-align:center"><B style="mso-bidi-font-weight:normal"><SPAN lang="EN-AU" style="font-size:14.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1">Y/N</SPAN></B></P></TD></TR><TR style="mso-yfti-irow:1;height:40.7pt"><TD width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN ASPART; INSULIN DEGLUDEC (RYZOGDEG 70/30)</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N203313</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">5866538</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:40.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">The sequence claimed in this patent consists
  of Asp(B28) human insulin which we don’t have. Furthermore, it involves the
  actual preparation of the “insulin with glycerol and or mannitol and 5-100mM
  of a halogen, including chloride and specifically <SPAN class="SpellE">NaCl</SPAN>.”</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">Whilst these are not relevant to us in the
  present stages of our projects – they have implications on how we plan to
  store the insulin in the future</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:40.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD></TR><TR style="mso-yfti-irow:2;height:10.7pt"><TD width="19%" rowspan="2" style="width:19.76%;border:solid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN GLARGINE RECOMBINANT (LANTUS/LANTUS SOLOSTAR)</SPAN></P></TD><TD width="11%" rowspan="2" style="width:11.9%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N021080</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">7476652</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Acidic insulin preparations with improved stability</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:3;height:10.7pt"><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">7713930</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">Similar to above – this involves a storage
  patent where a specific human insulin construct (glargine<SPAN class="GramE">),is</SPAN>
  preserved in <SPAN class="SpellE">polysorbate</SPAN> 20 and <SPAN class="SpellE">polysorbate</SPAN>
  80; with at least one preservative and water and a specific acidic <SPAN class="SpellE">pH.</SPAN></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">Again, this is an important consideration when
  it comes to the <SPAN class="GramE">long term</SPAN> storage of our insulin and
  its preparation.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:4;height:10.7pt"><TD width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN GLARGINE RECOMBINANT (APIDRA)</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N021629</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">6960561, 7452860, 7696162</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">Insulin preparations, which do not contain any zinc or
  only a small quantity of zinc and which have an improved stability</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">A formulation comprising at least one
  insulin <SPAN class="SpellE">analog</SPAN>; at least one surfactant; optionally
  at least one preservative; and optionally at least one of an <SPAN class="SpellE">isotonicizing</SPAN> agent, a buffer, and an excipient, wherein
  the pharmaceutical formulation is free from or contains less than 0.4% by
  weight of zinc based on the insulin content of the formulation.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">Importantly, our insulin (at the stage of
  our experimental work are currently left in storage buffer</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1"><O:P> </O:P></SPAN></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR><TR style="mso-yfti-irow:5;mso-yfti-lastrow:yes;height:10.7pt"><TD width="19%" style="width:19.76%;border:solid windowtext 1.0pt;border-top:
  none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">INSULIN LISPRO RECOMBINANT (HUMALOG KWIPEN)</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">N2057479</SPAN></P></TD><TD width="11%" style="width:11.9%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">6034054</SPAN></P></TD><TD width="51%" style="width:51.28%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1"><O:P> </O:P></SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;color:black;
  mso-themecolor:text1">STABLE INSULIN FORMULATIONS</SPAN></I></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">The stable insulin formulation claimed by
  this patent involves claim for a stable insulin solution with a <SPAN class="SpellE">i</SPAN>) physiologically tolerated buffer from the group
  of TRIS and arginine, and a
  ii) monomeric insulin analogue with human insulin that has a modified B28
  position and a modified B29 lysine or proline.</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;mso-fareast-font-family:&quot;Times New Roman&quot;;
  color:black;mso-themecolor:text1">Our sequence does not fall under these
  requirements in terms of modification and this patent thus would not affect
  us</SPAN></P><P class="MsoNormal" align="center" style="text-align:center"><I style="mso-bidi-font-style:normal"><SPAN lang="EN-AU" style="font-size:13.0pt;
  font-family:Quicksand;color:black;mso-themecolor:text1"><O:P> </O:P></SPAN></I></P></TD><TD width="5%" style="width:5.16%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt;
  mso-border-alt:solid windowtext .5pt;background:#F5C7CC;padding:0cm 5.4pt 0cm 5.4pt;
  height:10.7pt"><P class="MsoNormal" align="center" style="text-align:center"><SPAN lang="EN-AU" style="font-size:13.0pt;font-family:Quicksand;color:black;mso-themecolor:
  text1">N</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>